Ascendis Pharma: Funding, Investors & Team (Oct 2026)
Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.
Ascendis Pharma has raised $500M across 1 funding round on record, the most recent a Post-IPO Debt of $500M announced in Mar 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ascendis Pharma Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Ascendis Pharma Funding Rounds
Ascendis Pharma Founders and Leadership Team
No contact details are on record for this team yet.
Ascendis Pharma Funding Compared to Other Biotechnology Startups
Ascendis Pharma's latest round of $500M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ascendis Pharma in Biotechnology and Palo Alto
Companies Similar to Ascendis Pharma
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Ascendis Pharma Funding FAQs
What does Ascendis Pharma do?
Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.
How much funding has Ascendis Pharma raised?
Ascendis Pharma has raised $500M across 1 round on record. The most recent is a Post-IPO Debt of $500M announced in Mar 2022.
When did Ascendis Pharma last raise funding?
Ascendis Pharma's most recent funding round on record is a Post-IPO Debt of $500M, announced in Mar 2022.
Who is the CEO of Ascendis Pharma?
Jan Moller Mikkelsen is listed as CEO at Ascendis Pharma.
Where is Ascendis Pharma headquartered?
Ascendis Pharma is based in Palo Alto, California, United States.
How many employees does Ascendis Pharma have?
Ascendis Pharma is in the 501-1000 employee band.
How does Ascendis Pharma's funding compare to other Biotechnology startups?
Ascendis Pharma's latest round of $500M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Ascendis Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ascendis Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.